SciELO - Scientific Electronic Library Online

 
vol.27 número8La Tomografía por Emisión de Positrones (PET) en la práctica clínica oncológicaExpresión de CD44v6 en carcinomas escamosos de pulmón: Asociación con altas concentraciones de EGFR, proteína erbB2 y elevada proliferación celular índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

Compartir


Oncología (Barcelona)

versión impresa ISSN 0378-4835

Resumen

BOSCH ROIG, C. et al. Colorectal adenocarcinoma: survival prognostic factors of the adjuvant treatment with 5-fluorouracil-levamisole (5FU-Lev). Oncología (Barc.) [online]. 2004, vol.27, n.8, pp.26-34. ISSN 0378-4835.

PURPOSE: To assess the overall survival and the 5-year disease-free survival, and to investigate the prognostic factors of patients with stages II and III colorectal adenocarcinoma subjected to healing-intention surgery and adjuvant chemotherapy with 5-fluorouracil-levamisole (5-FU-LEV). MATERIAL AND METHODS: A cohort of 126 patients treated with 5-FU-LEV during 12 months were studied between September 1990 and November 1997. RESULTS: The number of infiltrated lymph nodes, and the vascular-lymphatic and perineural invasion were found to be significant prognostic factors in the mean overall survival and disease-free survival after 5 years. Bowel obstruction showed prognostic significance only in relation to the 5-year disease-free survival. CONCLUSIONS: The obtained results are similar to those reported in other large series published in the literature related with overall survival, disease-free survival and prognostic factors. Infiltrated lymph nodes remain as a significant prognostic factor in multivariate analysis.

Palabras clave : Colon cancer; Rectal cancer; Adjuvant chemotherapy; Prognosis study.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons